Albert Einstein College of Medicine

Team Liz and Raelan

Learn about ME/CFS through genome sequencing | Kernls

title

See the research focused on developing a deep understanding of ME/CFS through genomic sequencing. Donate directly today!

description

https://kernls.com/assets/images/og/project_foundation-to-treat-cfs.png

image

https://kernls.com/assets/images/og/twitter_project_foundation-to-treat-cfs.png

twitterImage

John Greally, DMed PhD, looks after patients as a clinical geneticist and is the Chief of the Division of Genomics in Einstein’s Department of Genetics. His areas of research are in medical genomics and the delivery of genomic information to enhance the health of the diverse Bronx population and the study of environmental effects and genetic influences on stem cell differentiation, among other genomic investigative work. He is co-principal investigator for the NIH-funded Center for Solutions for ME/CFS with colleagues from Columbia University in New York City.

Lead Researcher

Srilakshmi Raj, PhD, is a population geneticist who aims to understand why disease risk varies among individuals and ethnically diverse populations. Dr. Raj is a new recruit to Einstein and has previously studied at Cornell University, the University of Pennsylvania Department of Genetics, Harvard Medical School, the University of Oxford, and the University of Cambridge.

Einstein research teams have contributed to the world’s knowledge base in life-saving ways, including leading the largest early-stage breast cancer clinical trial in history. We also discovered a compound that makes cancer cells self-destruct while sparing healthy cells and drove the clinical trial into the first promising drug against COVID-19, among other notable breakthroughs.The research enterprise is growing quickly with $197.3 million in NIH funding earned in 2020.

Einstein research teams have contributed to the world’s knowledge base in life-saving ways, including leading the largest early-stage breast cancer clinical trial in history. We also discovered a compound that makes cancer cells self-destruct while sparing healthy cells and drove the clinical trial into the first promising drug against COVID-19, among other notable breakthroughs.

The research enterprise is growing quickly with $197.3 million in NIH funding earned in 2020.

Develop a deep understanding of ME/CFS through genomic sequencing

In this video, Dr. John Greally explains how a genome-wide association study never before performed on this scale can add tremendous value for future diagnostic testing and treatment opportunities for ME/CFS.

Especially when combined with key research and clinical efforts conducted through the Center for Solutions, a more robust genetic understanding of ME/CFS will continue to push the conversation forward, helping patients overcome hurdles to quality care.

In this video, Dr. John Greally explains how a genome-wide association study never before performed on this scale can add tremendous value for future diagnostic testing and treatment opportunities for ME/CFS.Especially when combined with key research and clinical efforts conducted through the Center for Solutions, a more robust genetic understanding of ME/CFS will continue to push the conversation forward, helping patients overcome hurdles to quality care.

Exciting news! I've been supporting and amplifying a research project positioned to help us better understand ME/CFS. Lead researcher Dr. Greally recently created a video message for me and my supporters about the long term implications of this project. 

I'm incredibly grateful for the generous support I've received as a Champion for Dr. Greally's work. I'm committed now more than ever to finish what I started! Hear directly from Dr. Greally, and donate today!

I'm excited to share a research update for the project I've been Championing. Hear directly from the lead researcher!